Zentalis to Cut 40% of Workforce to Back Development of Cancer-Drug Azenosertib
Zentalis Pharmaceuticals said it would cut 40% of its workforce as part of a restructuring to support the late-stage development of its cancer-drug azenosertib.
AstraZeneca, Daiichi’s drug cleared for wider use in breast cancer patients in US
Astra is due to pay Daiichi US$175 million in milestones after the US approval, the companies said. Enhertu is cleared in the ...
Food and Drug Administration wants to put nutrition labels front and center on food products
The U.S. Food and Drug Administration wants to put nutrition information front and center on food products to give consumers ...
phillyvoice.com2h
A new blood test accurately screens for colorectal cancer, researchers say
Research that has not yet been peer-reviewed shows the newest blood test is more than 80% accurate in detecting colon cancer ...
BioPharma Dive7h
Enhertu, with new FDA OK, set to supplant chemo in HER2-low breast cancer
The clearance is a step forward in AstraZeneca and Daiichi Sankyo’s plan to position antibody-drug conjugates like Enhertu ...
Futurism on MSN8h
Trump Administration Throws Cancer Research Into Turmoil
During Donald Trump's draconian first-week rollbacks, cancer research and other crucial medical projects have been paused ...
Texas Public Radio20h
The FDA pulls key DEI initiative for cancer studies from its website
A Food and Drug Administration project to promote diversity in clinical studies of cancer treatments was removed from the ...
Cure Today21h
FDA Approves Enhertu for HER2-Low and -Ultralow Breast Cancer
The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer ...
FDA bans red food dye due to potential cancer risk
The U.S. Food and Drug Administration has officially banned red dye — called Red 3, or Erythrosine — from foods, dietary ...
US FDA approves AstraZeneca's drug for breast cancer
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...
Monthly Prescribing Reference6h
Enhertu Approved for HR+, HER2-Low/Ultralow Metastatic Breast Cancer
Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...
Serial biotech entrepreneur targets obesity with drug fished out of bankruptcy court
A serial entrepreneur and a promising drug emerge from failed companies to pursue subsets of obesity patients, with or ...